AMRX (Amneal Pharmaceuticals) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMRX Amneal Pharmaceuticals Inc AMRX
56 GF Score
Price $17.85
GF Value $7.58
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Amneal Pharmaceuticals Net Loan?

Net Loan only applies to banks and insurance companies.

AMRX
56GF Score
Amneal Pharmaceuticals Inc AMRX
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of $17.85 is trading 135.5% above its estimated GF Value™ of $7.58. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for AMRX:

  • Net Loan:
  • GF Value™: $7.58 vs. price of $17.85 (135.5% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amneal Pharmaceuticals Business Description

Other Exchanges 2DT:Germany
Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
56GF Score

Get the complete analysis for AMRX

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.85
Price
$7.58
GF Value